Toll-like receptors and genital tract infection

International Journal of STD and AIDS

Volumn 21, Issue 3, 2010, Pages 153-157

  Sonnex, C ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Dendritic cell; Innate immunity; Sexually transmitted diseases; Toll like receptor

Indexed keywords

83M 002; ANTIGEN; CYTOKINE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; POLYINOSINIC POLYCYTIDYLIC ACID; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANTIGEN SPECIFICITY; B LYMPHOCYTE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONDYLOMA ACUMINATUM; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENITAL TRACT INFECTION; GONORRHEA; HERPES SIMPLEX; HOST; HUMAN; IMMUNIZATION; INNATE IMMUNITY; MOLECULAR MODEL; MYCOPLASMA; NATURAL KILLER CELL; NONHUMAN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATHOGENESIS; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SYPHILIS; T LYMPHOCYTE; TRICHOMONIASIS; UREAPLASMA; VAGINA CANDIDIASIS; VAGINITIS; WART VIRUS;

FEMALE; GENITALIA; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MALE; SEXUALLY TRANSMITTED DISEASES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTORS;

EID: 77949395167     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009525     Document Type: Review

References (53)

1. Janeway CA Jr, Medzhitov R. Innate immune system recognition. Ann Rev Immunol 2002;20:197-216
2. Hammerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr Opin Immunol 2005;17:29-35
3. Iijima N, Thompson JM, Iwasaki A. Dendritic cells and macrophages in the genitourinary tract. Mucosal Immunol 2008;1:451-9
4. MacNeill C, Umstead TM, Phelps DS, et al. Surfactant protein A, an innate immune factor, is expressed in the vaginal mucosa and is present in vaginal lavage fluid. Immunology 2004;111:91-9
5. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-45
6. Medzhitov R. TLR-mediated innate immune recognition. Semin Immunol 2007;19:1-2
7. Imler JL, Zheng L. Biology of Toll receptors: lessons from insects and mammals. J Leukoc Biol 2004;75:18-26
8. O'Connell RM, Saha SK, Cheng G. Combating microbial pathogens through host defense gene programs. Curr Immunol Rev 2005;20:1372-8
9. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2001;7:179-90
10. O'Connell CM, Ionova IA, Quayle AJ, Visintin A, Ingalls RR. Localisation of TLR2 and MyD88 to Chlamydia trachomatis inclusions. Evidence for signalling by intracellular TLR2 during infection with an obligate intracellular pathogen. J Biol Chem 2006;281:1652-9
11. Heine H, Müller-Loennies S, Brade L, Lindner B, Brade H. Endotoxic activity and chemical structure of lipopolysaccharides from Chlamydia trachomatis serotypes E and L2 and Chlamydophila psittaci 6BC. Eur J Biochem 2003;270:440-50
12. Vabulas RM, Ahmad-Nejad P, da Costa C, et al. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001;276:31332-9
13. Darville T, O'Neill JM, Andrews CW Jr, Nagarajan UM, Stahl L, Ojcius DM. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol 2003;171:6187-97
14. Fisette PL, Ram S, Andersen JM, Guo W, Ingalls RR. The lip lipoprotein from Neisseria gonorrhoeae stimulates cytokine release and NF-kappaB activation in epithelial cells in a Toll-like receptor 2-dependent manner. J Biol Chem 2003;278:46252-60
15. Massari P, Henneke P, Ho Y, Latz D, Golenbock DT, Wetzler LM. Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. J Immunol 2002;168:1533-7
16. Singleton TE, Massari P, Wetzler LM. Neisserial porin-induced dendritic cell activation is MyD88 and TLR2 dependent. J Immunol 2005;174:3545-50
17. Fichorova RN, Cronin AO, Lien E, Anderson DJ, Ingalls RR. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signalling. J Immunol 2002;168:2424-32
18. Witkin SS, Linhares IM, Giraldo P, Ledger WJ. An altered immunity hypothesis for the development of symptomatic bacterial vaginosis. Clin Infect Dis 2007;44:554-7
19. Zariffard MR, Novak RM, Lurain N, Sha BE, Graham P, Spear GT. Induction of tumor necrosis factor-alpha secretion and toll-like receptor 2 and 4 mRNA expression by genital mucosal fluids from women with bacterial vaginosis. J Infect Dis 2005;191:1913-21
20. Libby EK, Pascal KE, Mordechai E, Adelson ME, Trama JP. Atopobium vaginae triggers an innate immune response in an in vitro model of bacterial vaginosis. Microbes Infect 2008;10:439-46
21. Genc MR, Vardhana S, Delaney ML, et al. Relationship between a toll-like receptor-4 gene polymorphism, bacterial vaginosis-related flora and vaginal cytokine responses in pregnant women. Eur J Obstet Gynecol Reprod Biol 2004;116:152-6
22. Verstraelen H, Verhelst R, Nuytinck L, et al. Gene polymorphisms of Toll-like and related recognition receptors in relation to the vaginal carriage of Gardnerella vaginalis and Atopobium vaginae. J Reprod Immunol 2009;79:163-73
23. McGowin CL, Ma L, Martin DH, Pyles RB. Mycoplasma genitalium-encoded MG309 activates NF-kappaB via Toll-like receptors 2 and 6 to elicit proinflammatory cytokine secretion from human genital epithelial cells. Infect Immun 2009;77:1175-81
24. Shimizu T, Kida Y, Kuwano K. A triacylated lipoprotein from Mycoplasma genitalium activates NF-kappaB through Toll-like receptor 1 (TLR1) and TLR2. Infect Immun 2008;76:3672-8
25. Shimizu T, Kida Y, Kuwano K. Ureaplasma parvum lipoproteins, including MB antigen, activate NF-kappaB through TLR1, TLR2 and TLR6. Microbiology 2008;154:1318-25
26. Zariffard MR, Harwani S, Novak RM, Graham PJ, Ji X, Spear GT. Trichomonas vaginalis infection activates cells through toll-like receptor 4. Clin Immunol 2004;111:103-7
27. Chang JH, Park JY, Kim SK. Dependence on p38 MAPK signalling in the up-regulation of TLR2, TLR4 and TLR9 gene expression in Trichomonas vaginalis-treated HeLa cells. Immunology 2006;118:164-70
28. van der Graaf CA, Netea MG, Verschueren I, van der Meer JW, Kullberg BJ. Differential cytokine production and toll-like receptor signalling pathways by Candida albicans blastoconidia and hyphe. Infect Immun 2005;73:7458-64
29. Jouault T, Ibata-Ombetta S, Takeuchi O, et al. Candida albicans phospholipomannan is sensed through toll-like receptors. J Infect Dis 2003;188:165-72
30. Li M, Chen Q, Shen Y, Liu W. Candida albicans phospholipomannan triggers inflammatory responses of human keratinocytes through Toll-like receptor 2. Exp Dermatol 2009;18:603-10
31. Roeder A, Kirschning CJ, Rupec RA, Schaller M, Korting HC. Toll-like receptors and innate antifungal responses. Trends Microbiol 2004;12:44-9
32. Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge: role of toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002;169:10-14
33. Salazar JC, Pope CD, Moore MW, Pope J, Kiely TG, Radolf JD. Lipoprotein-dependent and -independent immune responses to spirochetal infection. Clin Diagn Lab Immunol 2005;12:949-58
34. Bouis DA, Popova TG, Takashima A, Norgard MV. Dendritic cells phagocytose and are activated by Treponema pallidum. Infect Immun 2001;69:518-28
35. Kim WY, Lee JW, Choi JJ, et al. Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer 2008;18:300-5
36. Lee JW, Choi JJ, Seo ES, et al. Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog 2007;46:941-7
37. Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007;178:3186-97
38. Fahey LM, Raff AB, Da Silva DM, Kast WM. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol 2009;182:2919-28
39. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003;198:513-20
40. Gill N, Deacon PM, Lichty B, Mossman KL, Ashkar AA. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. J Virol 2006;80:9943-50
41. Sato A, Linehan MM, Iwasaki A. Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. Proc Natl Acad Sci USA 2006;103:17343-8
42. Gill N, Davies EJ, Ashkar AA. The role of Toll-like receptor ligands/agonists in protection against genital HSV-2 infection. Am J Rep Immunol 2008;59:35-43
43. Herbst-Kralovetz MM, Pyles RB. Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J Virol 2006;80:9988-97
44. Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 2004;190:1841-9
45. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001;166:3451-7
46. Kwant A, Rosenthal KL. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 2004;22:3098-104
47. Pyles RB, Higgins D, Chalk C, et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol 2002;76:11387-96
48. Sajic D, Ashkar AA, Patrick AJ, et al. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol 2003;71:561-8
49. Zhang X, Chentoufi AA, Dasgupta G, et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2009;2:129-43
50. Mark KE, Corey L, Meng TC, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis 2007;195:1324-31
51. Fife KH, Meng TC, Ferris DG, Liu P. Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions. Antimicrob Agents Chemother 2008;52:477-82
52. Hornef MW, Henriques-Normark B, Normark S. The function and biological role of toll-like receptors in infectious diseases: an update. Curr Opin Infect Dis 2008;21:304-12
53. Beutler BA. TLRs and innate immunity. Blood 2009;113:1399- 407